KoBioLabs, Inc (KOSDAQ: 348150)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,270.00
+70.00 (1.13%)
Sep 12, 2024, 9:51 AM KST
-49.19%
Market Cap 119.15B
Revenue (ttm) 52.08B
Net Income (ttm) -11.10B
Shares Out 19.37M
EPS (ttm) -585.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,322
Open 6,170.00
Previous Close 6,200.00
Day's Range 6,170.00 - 6,340.00
52-Week Range 5,980.00 - 14,150.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About KoBioLabs

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases. The company is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO GwangPyo Ko
Employees 50
Stock Exchange KOSDAQ
Ticker Symbol 348150
Full Company Profile

Financial Performance

In 2023, KoBioLabs's revenue was 33.14 billion, an increase of 185.54% compared to the previous year's 11.61 billion. Losses were -13.85 billion, -36.81% less than in 2022.

Financial Statements

News

There is no news available yet.